Claims
- 1. A method of inhibiting cellular proliferation comprising inhibiting the activity or reducing the amount of a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs. 243-357 and SEQ ID NOs. 359-398 or inhibiting the activity or reducing the amount of a nucleic acid encoding said polypeptide.
- 2. The method of claim 1, wherein the cell in which proliferation is inhibited is selected from the group consisting of Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacter cloacae, Helicobacter pylori, Neisseria gonorrhoeae, Enterococcus faecalis, Streptococcus pneumoniae, Haemophilus influenzae, Salmonella typhimurium, Saccharomyces cerevisiae, Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Klebsiella pneumoniae, Salmonella typhi, Salmonella paratyphi, Salmonella cholerasuis, Staphylococcus epidermidis, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema pallidum, Bacillus anthracis, Yersinia pestis, Clostridium botulinum, Campylobacter jejuni, Chlamydia trachomatus, Chlamydia pneumoniae or any species falling within the genera of any of the above species.
- 3. The method of claim 1, wherein the cell in which proliferation is inhibited is Escherichia coli.
- 4. A method for inhibiting cellular proliferation comprising introducing a compound which inhibits the activity or reduces the amount of a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs. 243-357 and SEQ ID NOs. 359-398 or which inhibits the activity or reduces the amount of a nucleic acid comprising a nucleotide sequence encoding said polypeptide into a cell.
- 5. The method of claim 4, wherein said compound is an antisense nucleic acid.
- 6. The method of claim 5, wherein said compound is an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs.: 405-485, or a proliferation-inhibiting portion thereof.
- 7. The method of claim 6, wherein said proliferation inhibiting portion of one of SEQ ID NOs. 405-485 is a fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOs: 405-485.
- 8. The method of claim 4, wherein said compound is a triple helix oligonucleotide.
- 9. The method of claim 4, wherein the cell in which proliferation is inhibited is selected from the group consisting of Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacter cloacae, Helicobacter pylori, Neisseria gonorrhoeae, Enterococcus faecalis, Streptococcus pneumoniae, Haemophilus influenzae, Salmonella typhimurium, Saccharomyces cerevisiae, Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Klebsiella pneumoniae, Salmonella typhi, Salmonella paratyphi, Salmonella cholerasuis, Staphylococcus epidermidis, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema pallidum, Bacillus anthracis, Yersinia pestis, Clostridium botulinum, Campylobacter jejuni, Chlamydia trachomatus, Chlamydia pneumoniae or any species falling within the genera of any of the above species.
- 10. The method of claim 4, wherein the cell in which proliferation is inhibited is Escherichia coli.
- 11. A method for inhibiting cellular proliferation comprising introducing a compound with activity against a gene corresponding to one of SEQ ID NOs.: 82-242 or with activity against the product of said gene into a population of cells expressing a gene.
- 12. The method of claim 11, wherein said compound is an antisense nucleic acid.
- 13. The method of claim 12, wherein said compound is an antisense oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NOs.: 405-485, or a proliferation-inhibiting portion thereof.
- 14. The method of claim 13, wherein said proliferation inhibiting portion of one of SEQ ID NOs. 405-485 is a fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOs: 405-485.
- 15. The method of claim 11, wherein said compound is a triple helix oligonucleotide.
- 16. The method of claim 11, wherein the cell in which proliferation is inhibited is selected from the group consisting of Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacter cloacae, Helicobacter pylori, Neisseria gonorrhoeae, Enterococcus faecalis, Streptococcus pneumoniae, Haemophilus influenzae, Salmonella typhimurium, Saccharomyces cerevisiae, Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Klebsiella pneumoniae, Salmonella typhi, Salmonella paratyphi, Salmonella cholerasuis, Staphylococcus epidermidis, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema pallidum, Bacillus anthracis, Yersinia pestis, Clostridium botulinum, Campylobacter jejuni, Chlamydia trachomatus, Chlamydia pneumoniae or any species falling within the genera of any of the above species.
- 17. The method of claim 11, wherein the cell in which proliferation is inhibited is Escherichia coli.
RELATED APPLICATIONS
[0001] This application is a divisional application from U.S. patent application Ser. No. 09/492,709, filed Jan. 27, 2000 which claims priority to U.S. Provisional Patent Application Serial No. 60/117,405 filed Jan. 27, 1999. The disclosures of U.S. patent application Ser. No. 09/492,709 and U.S. Provisional Patent Application Serial No. 60/117,405 are incorporated herein by reference in their entireties.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60117405 |
Jan 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09492709 |
Jan 2000 |
US |
Child |
09912020 |
Jul 2001 |
US |